Monday, May 26, 2014

NevBio to have President of Roseman University of Health Sciences, Renee Coffman, speak on the Roseman Teaching Method

Dr. Renee Coffman, President of Roseman University of Health Sciences, will speak on Tuesday, May 20, 2014 on the the "Roseman Method",

The Roseman Method is an innovative teaching method:
1. Block Curriculum. Each class is an immersion into the topic with one course at a time, six hours a day for five days a week, which allows students to completely focus on that topic to gain a deeper understanding.
2. Content Mastery. Roseman does not have grades. Students either pass or fail. To pass the students must achieve 90% on all tests.
3. Variety of Teaching Methods. Roseman understands that students learn the material in different ways which is why they employ several methods of teaching - lecture, hands-on, experimental and real-life situations.
4. Collaboration. Students must work together as part of the learning process. Because students are not graded, there is no competition between students. Students feel free to help other. It's a positive environment.

"When You Build a University from Scratch, You are Free to Invent and Improve on the Status Quo."

The results are impressive. Roseman students in Pharmacy, Nursing and Dental Medicine consistently pass 95% on their first time on their examination boards.

Dr. Renee Coffman is the president and co-founder of Roseman University which offers Colleges of Pharmacy, Nursing and Dental Medicine, an MBA program and has more than 1,000 students. She holds a pharmacy degree from Ohio Northern University and her doctorate is in industrial and physical pharmacy from Purdue University.

Dr. Coffman's mentor is co-founder, Dr. Harry Rosenberg. He taught her that whether it's a student in a classroom or an employee, no one walks in hoping to fail. "Your main focus is really simple-it's to help that individual succeed. I strive every day to ensure that my students can succeed in the classroom and that people who work for Roseman have opportunity to succeed in their jobs," she told the Las Vegas Woman Magazine, May 2013.

Sunday, May 4, 2014

City of Las Vegas to Talk About $1 Million Grant for Contest for Best Idea for Las Vegas on April 30, 2014

The City of Las Vegas launches Strong Cities, Strong Communities Challenge: $900,000 of cash prizes available for effective solutions to help grow the local economy.

The Strong Cities, Strong Communities (SC2) Challenge is a prestigious international competition that will award $900,000 in prizes for the most innovative, creative & transformational economic development plans to help revitalize targeted areas within the city. 

The SC2 Challenge is federally funded by a $1 million grant from the U.S. Department of Commerce's Economic Development Administration (EDA). It was awarded in 2012 to three U.S. cities:  Las Vegas, Nevada; Greensboro, North Carolina; and Hartford, Connecticut.

The goal of the competition is to assist participating cities, including Las Vegas, in cultivating well-conceived, innovative ideas to revitalize four targeted areas within the community:  Cashman Center, the Las Vegas Medical District, business parks, and existing Redevelopment projects.

Bill Arent is the Director of Economic & Urban Development Department for the the City of Las Vegas. The Office creates, coordinates and encourages new development and redevelopment in Las Vegas, with an emphasis on the downtown area. It strives to increase and diversify the city's economic base through business attraction, retention and expansion programs. He was promoted to this position in October 2009. Employed with the city since 1997, Arent has held numerous positions in housing development, economic development and redevelopment. He was the senior project manager for Symphony Park, and has negotiated development agreements for the Cleveland Clinic Lou Ruvo Center for Brain Health and The Smith Center for the Performing Arts. 
Arent holds a Bachelor of Arts in Economics from the University of Pennsylvania and a Master of Public Administration from the University of Nevada, Las Vegas. He is certified as an economic development finance professional.

Medical Marijuana: Talk by Tick Segerblom & Bio-Chemistry by UNLV Scientist, Martin Schiller on March 26, 2014

Richard "Tick" Segerblom is a Nevada State Senator. He was first elected to the Nevada Assembly in 2006. He was elected to the Nevada State Senate in 2012 to represent Senate District 3. He is a fourth generation Nevada representative. His mother, Gene Segerblom (née Wines), served in the Nevada Assembly from 1992 through 2000 and was a member of the Boulder City Council. His grandmother, Hazel Wines (née Bell), served in the Nevada Assembly from 1934 - 1936 representing Humboldt County. Segerblom's great-grandfather was William "Johnny" Bell representing Humboldt County from 1906 to 1914 in the Nevada Senate. Segerblom was Chairman of the Nevada Democratic Party from 1990 to 1994.
Segerblom represents Senate District 3 which encompasses a portion of urban Clark County including portions of the City of Las Vegas. 
Tick is also a practicing attorney.

Nevada Set to Make Millions on Medical Marijuana
According to an article in the Las Vegas Review-Journal last July, Tick Segerblom told a group that pot dispensary owners in Nevada are in a perfect position to make millions of dollars because the state is the only one in the country that plans to accept out-of-state medical marijuana cards.
State Senator Tick Segerblom helped pass the law (3) that helped legalize the dispensaries. As reported, Tick believes that the medical marijuana business to be a boon not only for state coffers but also for the 40 operators who will be able to sell medical pot to anybody who holds a card from another state.

At last tally 19 states had legalized medical marijuana - from Colorado to Oregon and Washington to Connecticut, Vermont and Delaware.

Tick went on to say that "...with the millions of people who visit here, I don't need to tell you how profitable it can be. And Nevada needs the money. It's very short on revenue. But we're not going to become a Venice Beach. Nevada has a thorough and fair bill, and we're going to regulate this industry the right way." 

NevBio to host Zach Miles, Esq., the New Director of Tech Transfer at UNLV on February 26, 2014

Zach Miles, Esq. was hired in November 2013 as the Executive Director of UNLV Technology Transfer and Development. His job is to manage the commercialization of intellectual property owned by UNLV. Prior to UNLV, Miles worked with the Tech Venture & Commercialization at the University of Utah where he helped numerous startups. 

He was the Deputy Executive Director when University of Utah was named the top university in the country for creating startup companies (something needed in Southern Nevada) by the Association of University Technology Managers, beating out schools such as MIT, Johns Hopkins and Purdue.

He has a BS in Microbiology from Weber State University and a JD from the University of New Hampshire School of Law.

NevBio's Deans' Talk & Legislator Luncheon on January 21, 2014

NevBio is sponsoring our first "Deans' Talk" with two science deans. They will talk about the increasing demand for science education for careers in medicine and research:
* How is Southern Nevada meeting this demand?
* What are the accomplishments?
* How do we prepare for Southern Nevada's medical & biomedical future?

Timothy L. Porter, PhD. was hired as the Dean of the UNLV College of Sciences. He was a professor of physics and astronomy at Northern Arizona University.  He served as the director of the university's Growing Biotechnology Initiative. He holds five U.S. patents for the development of specialized sensors. Prior to his time at NAU, Porter served as a research associate at Arizona State University and as a staff physicist for the Hughes Aircraft Company.
Porter earned a Ph.D. in physics from Arizona State University in 1988. He received M.S. and B.S. degrees in physics from California State University.

Andy Kuniyuki, PhDcurrently serves as the Dean of Liberal Arts and Sciences at Nevada State College. He received his B.S. in biology from the University of Hawaii and his Ph.D. in genetics from the University of California. Dr. Kuniyuki's belief that Biology is preeminent began with his study of the Hawaiian Drosophila and continued with his many research endeavors employing monoclonal antibody, tissue culture, oligonucleotide and immunodiagnostic technologies. 

Dr. Kuniyuki's passion for teaching took him deep within the cellblocks of San Quentin Prison where he taught genetics to a captured audience while completing his doctorate at Berkeley. 

NevBio Welcomes Trevor Dardik, CEO & Founder of UniTsem at December 12, 2013 Luncehon

Trevor was invited by the Downtown Project to stay at Tony Hsieh's crash pad. The crash pad is a set of condos for important visitors such as entrepreneurs, company founders & CEOs. 

Trevor Dardik is the CEO & Co-founder of UniTsem. He was the president of LifeWaves International LLC for five years.  LifeWaves monitors 11 different bioindicators to understand how the body responds to exercise. It uses the HeartWave Cycles Exercise® Program and state-of-the-art Rhythmic Biofeedback system to improve one's health. 
Trevor has a BAIS in Biology from Fairleigh Dickinson University in Hackensack, NJ and was a former professional track athlete.

Trevor will talk about the wearable EKG monitor that his company is delivering along with other medical devices products his Italian company is selling in Europe.

NevBio and CEO-CFO International Hosts Delegation from Kazakhstan on Nov 20, 21 & 22, 2013

NevBio and the CEO-CFO Group International hosted of delegation of professors, governmental officials and businessmen for three days of classes at the Mansion formerly owned by Mike Tyson which is now owned by Equiinet International.

During the three days, the delegation attended classes and tours of businesses. Speakers included Richard Helfrich who spoke on creating innovation in the United States and other countries. Steve Curtis spoke on Unmanned Aerial Vehicles in Nevada and its future in the world. Dr. Oliver Hemmers spoke on common challenges that Kazakhstan and Nevada face. Zane Wilson, CEO of GMIS spoke about the medical isotope industry. Leith Martin, CEO of Equiinet spoke about small business innovation and their company's product which is one box to handle voice, internet, security and backup. Matthew Waymire talked about how Americans "tinker" and develop new products - new products that came out of garages such as Apple, Hewlett Packard and others. Kent Rippy talk about marketing and social media. Former Congresswoman Shelley Berkley spoke about her relationship with Kazakhstan and how she helped the US work closer with Kazakhstan.

Trips were taken to the University of Nevada of Las Vegas (UNLV) College of Sciences, UNLV Gaming Institute and UNLV College of Engineering. The delegation visited with Dr.Andy Kunuki at Nevada State College where they discussed new teaching methods. The group toured the Atomic Testing Museum. Kazakhstan also hosted USSR's nuclear testing site.

Wednesday, April 30, 2014

NevBio to Join the SciTech Showcase & Dinner on October 24, 2013

Last Day to Buy Tickets:  SciTech Showcase & Dinner on Oct 24, 2013 in Las Vegas at the World Market Center


Nancy Phillips, CEO of ViaWest
One of the Largest Privately Owned Data-Center Companies in the Nation  
Darik Volpa, CEO of
Named "Most Inspiring" by PharmaVOICE
Thursday, October 24, 2013
4 pm Showcase & Cocktails
6 pm Dinner & Program
World Market Center
RSVP here
Last day to buy tickets (Oct 15th)

Don't Miss the Exhibitors: 
NevBio, Actus Biotechnologies, BridgeBank, 
BNY Mellon, Brennan Capital Partners, 
Bruce & Banka CPAs, The City of Henderson, 
City National Bank, Cleveland Clinic, CorCell, 
Equon Pharmaceuticals, Inc., Hamilton Lane, 
Howard & Howard, Las Vegas Business Press, 
Las Vegas Internet Hospital, 
Lucine Biotechnology,Inc., Maverick Angels, 
Nevada State College, Phoenix Staff, Quantion Advisors, Quertle, SableSystems, Skinvisible Pharmaceuticals, Ubiquita,,
Varian Medical Systems & ViaWest. 

Join researchers, friends, co-workers & supporters of science and technology in Southern Nevada.

NevBio Recognizes Cancer Researchers In Southern Nevada

Nevada Biotechnology & Health Science Consortium
and Lionel Sawyer & Collins 
are pleased to host a Cocktail Party 
Cancer Researchers in Southern Nevada
Saturday, September 28, 2013
6 pm to 10 pm
At the Loft of Mohamed Iqbal, Esq. 
Soho Lofts Unit 807, 900 Las Vegas Boulevard South, Las Vegas, Nevada 89101
No Cost to attend, please RSVP
*Limited Room*

Come join fellow researchers, friends, co-workers & supporters. Please forward this email to others that might want to attend. 

The Nevada Biotechnology & Health Science Consortium wants to recognize those who continue to research treatments for cancer in Southern Nevada and those who have supported, continue to support and/or are interested in cancer research in Southern Nevada. PleaseRSVP.

We are asking researchers to provide an update on their current work in Southern Nevada by giving a brief 5 minute talk at the event (limited spots).

We want to thank our host, Mohamed Iqbal, a litigator with Lionel Sawyer & Collins, whose practice includes international pharmacovigilance and negotiating clinical research agreements. He also addresses IP protection issues, advises start-ups, and has appeared before an FDA Advisory Board in Washington, D.C.

Growing a Life Science industry in Las Vegas is achievable.

Ross Newman will speak at the September 11, 2013 NevBio luncheon. He believes that if a biotech industry is going to be created in Las Vegas it will need: 

1) Commitment - by talented and hardworking people that will ultimately benefit from a biotech industry:
*Experienced Management personnel in pharma/biotech
*Regulatory & Clinical study management
2) Risk Capital & equity man hours 
3) Faith (not hope)

Join us for this discussion on the future of biotechnology in Las Vegas.

Ross Newman, CEO of Innovative Health Research to Speak on the Creation of a Biotech Cluster in Southern Nevada

Ross W. Newman will speak at the NevBio meeting on September 11, 2013. He began his  30+ year career in pharmaceutical/biotech research working as a West Coast correspondent of the investment banking firm Allen & Co. In that role, he directed capital into-and sat on the board of directors of-many early biotech start-ups developed from research coming out of the University of California, San Francisco and Stanford University. As one of the start-ups was failing, he was selected by the board to become the company's new CEO. Newman was just in his 20's when he directed the shut-down and merger into Xoma, Inc. of one of the first monoclonal antibody companies in the country to go into clinical trials and fail. Early in his career, he lost a couple million dollars of his own money (most of which was borrowed, he says) and close to $20 million of investor money. It took until 1996 to pay off his debt. Newman earned a BA in Political Demography from the University of California, Berkeley in 1971. After graduating, he traveled. In 1973, he returned to Berkeley where he completed his doctoral dissertation in epistemology in 1977.

Sunday, July 14, 2013

Patent Attorney, Seaton Currran to Speak at August 8th, 2013 NevBio Luncheon

Seaton Curran, J.D., MBA & P.E. of Howard & Howard will speak on 
"New Laws - New Strategy: How the Recent Changes in Patent Law Affect your IP Strategy", Thursday, August 8th, 11:30 am check-in, 12 lunch & talk, McCormick & Schmicks, $30. (Students & researchers are free)

This year, the most significant changes in patent law in over 50 years went into effect as the America Invents Act continues to be implemented.  As these new laws come into effect, businesses and inventors need to reevaluate their Intellectual Property strategies to adjust to the new changes.  The most significant change was implemented in March 16, 2013 when the Patent system changed from "First to invent" to "First Inventor to File".  Mr. Curran will discuss IP strategy and how the new patent laws affect the protection of your intellectual property.
Mr. Curran is an attorney with the law firm of Howard & Howard and concentrates his practice on intellectual property.  He advises clients in the development intellectual property strategies with a focus on maximizing business value through the protection and licensing of business assets.  He concentrates his practice in the area of patent law with experience in mechanical, electrical and computer software technologies, and assists client with the preparation and prosecution of U.S. and foreign patent applications, trademark registrations, patentability searches, patent landscape analysis, freedom-to-operate, infringement analyses and invalidity opinions.  Mr. Curran received his J.D. from the University of Nevada Las Vegas, M.B.A. from the University of Southern California, and BS in engineering from Loyola Marymount University.  He is licensed to practice in Nevada and before the USPTO, and holds a professional engineering license in Nevada.

Seaton Curran has presented to NevBio before. He gives an exceptional presentation. I would advise you not to miss his talk.
John Laub
Nevada Biotechnology & Health Science Consortium

Dr. Ron Kline, Pediatric Oncologist to Speak on the Health Insurance Exchange on July 12, 2013

Dr. Ron Kline will speak on "Nevada's Health Insurance Exchange -
A Doctor's Point of View" Friday, July 12th, 11:30 Check-in, 12 noon lunch & talk McCormick & Schmicks.

Ronald Kline is a pediatric hematologist-oncologist and pediatric bone marrow transplant physician. 

In 2011 he was appointed by Governor Sandoval to the Board of Directors of the Silver State Health Insurance Exchange.

Dr. Kline is the author of 20 scientific articles, as well as the editor of a textbook on pediatric bone marrow transplantation 

He earned his medical degree from UCLA. His postgraduate clinical training was at the Children's Hospital of Los Angeles and UCSF. In addition, he completed a research fellowship at the National Cancer Institute, publishing work on the immunotherapy of cancer.

He was the President of the Clark County Medical Society. 
He was the President of the Nevada State Medical Association.

CCCNHe is a doctor with Comprehensive Cancer Centers of Nevada and has lived in Las Vegas for 10 years.

Come hear an in-depth explanation of the new Silver State Health Insurance Exchange that will be starting enrollment on October 1st for coverage to start on January 1, 2014. 
Dr. Ron Kline is a past president of the Clark County Medical Society and the Nevada State Medical Association and is now a Director of the Silver State Health Exchange.
Health Insurance Exchange Facts:
* There is no delay on implementation of the
requirement of health insurance by 2014
* There is no delay in implementing Nevada's Health Insurance Exchange.
* There is a delay for the large employer mandate to 2015 but it does not affect the Insurance Exchange
* There are 588,000 Nevadans that don't have health insurance.
* Nevadans will be penalized in 2014 for not having health care.
* Enrollment for the exchange starts on October 1st for coverage on January 1st.
The Affordable Care Act will change health care. It will affect the medical industry. Ron Kline is one of the Directors of the Health Insurance Exchange in Nevada. He was also awarded a fellowship from the Robert Wood Johnson Foundation. Don't miss this opportunity to learn about the changes that are coming. 

Tuesday, May 28, 2013

Dr. Craig Dees, CEO of Provectus - Promising Results in Phase II for Melanoma - June 5, 2013

Please join us - NevBio evening event:
Dr. Craig Dees, CEO of Provectus Pharmaceuticals, Inc.
"Promising Results with Melanoma Lesions in Phase II Trial of 80 subjects"
Wednesday, June 5th, 5:30 pm
Panevino Restaurant (New location)
RSVP here. $10 (Students, researchers & anyone involved in cancer - no charge)

Provectus Pharmaceuticals, an oncology and dermatology biopharmaceutical company which is conducting Phase 2 trials of its drug, PV-10 as a treatment for metastic melanoma.

PV-10 selectively destroys cancer cells without harming surrounding healthy tissue. As reported in Practical Dermatology, the phase II open label, single-arm trial, 80 subjects with AJCC Stage III/ IV melanoma received treatment for one to 10 target lesions and up to 10 non-target lesions; at least one target lesion had to have biopsy confirmation of the diagnosis. Target lesions were >0.2cm diameter. Intralesional dosing was provided at 50 percent of the calculated lesion volume. Retreatment was allowed at weeks 8, 12, or 16, and all subjects were followed for 52 weeks.

According to final outcome data provided by Provectus, a Complete Response (CR: complete disappearance of the tumor) of PV-10 injected lesions was achieved in 26 percent of subjects, Partial Response (PR: at least a 30 percent reduction in tumor volume) was seen in 25 percent of subjects, and Stable Disease (SD: less than 20 percent increase in tumor volume) was seen in 18 percent of subjects. Less than one-third (31 percent) of subjects experienced Disease Progression (DP: 20 percent or greater increase in tumor volume).
Dr. Craig Dees & Provectus have had impressive results from their Phase 2 study and are preparing for Phase 3.

We want to thank Dominic Rodrigues for generously supporting the effort to have Dr. Dees speak in Las Vegas.

There's a lot more to the story of Dr. Dees & Provectus. I hope you can join us on Wednesday, June 5th. 

Cord Blood America - Saving the Lives of the those Closest to You - May 17, 2013

Join us CEO of Cord Blood America,
Joseph Vicente & Dr. Geoffrey O'Neill
Date:  Friday, May 17th
11:30 am check-in, 12 noon lunch/talk
Place: McCormick & Schmicks
Cost: $30 here. (Students & Researchers are free)

Joseph R. Vicente, has been the Chairman and President at Cord Blood America Inc. since May 15, 2012. Mr. Vicente had served as the Chief Operating Officer/VP and as the VP of Corporate Strategy at Cord Blood America Inc. He had earlier co-founded The Empower Network, Inc. He served as the President and Chief Operating Officer of The Empower Network, Inc. Joe has been a Director of Cord Blood America Inc. since June 2004. He earned an MBA from the University of Tampa.

Dr. Geoffrey O'Neill, who will also be speaking, has 25 years experience in the stem cell industry, has published 78 papers on the sector. He was the recipient of the prestigious Jean Julliard Price for Research from the International Society of Blood Transfusion and the International Society of Hematology.

 Cord Blood America preserves cord blood at the birth of a child for potential use in future stem cell therapy. The umbilical cord contains a rich store of stem cells.

Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases: leukemia, severe anemia, metabolic blood disorders,  immune deficiencies and seventy other diseases.

NevBio Luncheon - Van Vo, Cancer Researcher at UNLV on April 30, 2013

Van Vo, Cancer Researcher at UNLV
Tuesday, April 30th
McCormick & Schmicks
11:30 am check-in, 12 noon lunch & talk
RSVP here. $30. Students & researchers, no cost.

Van Vo is a PhD candidate at UNLV. Her research involves developing cisplatin analogues for the treatment of cancer
The In Vitro Cytotoxic Effects of Cisplatin Analogues in Cancer and Normal Cells by Van Vo, Ontida Tanthmanatham, Haesook Han, Pradip K. Bhowmik and Bryan L. Spangelo, UNLV Department of Chemistry

About 50% of cancer chemotherapeutic regimens consist of platinum-based drugs. Cisplatin (CDDP) was the first platinum(II) complex approved for clinical treatment by the U.S. Food and Drug Administration (FDA) in 1978. Along with cisplatin, two other platinum(II) complexes, carboplatin and oxaliplatin, are now approved for use worldwide.
Although commonly prescribed, clinical application of platinum drugs is limited due to narrow spectra of activity, cellular resistance, and toxic side effects. As a consequence of
these drawbacks, the search for improved drugs continues with the goal of discovering compounds with greater efficacy and reduced toxicity.
Cisplatin is not routinely used for the treatment of breast cancer since many breast cancers are resistant to cisplatin treatment; however, it has been reported that some breast
cancers are sensitive to cisplatin. In an effort to develop improved platinum drugs for the treatment of breast cancers, new platinum-complexes have been synthesized.

 In vitro studies in various human breast cancer cells demonstrated that these compounds are much more potent than cisplatin. One of the synthesized complexes was also tested in a normal human breast cell line and was found to be more toxic to the normal cells compared to cancer cells. However, when this compound was tested in vivo in a mouse model, the animals survived after administration of the compound at a dose of 12.5 mg/kg/day for three days. Further studies are required to assess the potential translation of these compounds into clinical use.

Crohn's Disease & Ulcerative Colitis at NevBio - Thurs, April 25, 2013

Thursday, April 25th, 12 Noon
Glenn Diamond, Red Green Biotechnology
 McCormick & Schmicks
11:30 Check-in, 12 pm lunch & talk.
$30. (students & researchers free)

"Crohn's Disease & Ulcerative Colitis"
Red Green Biotechnology launch against inflammatory bowel disease epidemic. Innovate Nevada's first parade entrepreneur.
Glenn Diamond is the Founder of Neuropeptide Dynamics and David Pharmaceuticals. He is a polymath featured in Fortune (see article on left) for smart drug development work. One of the last disciples of Bob Swanson immortal founder of Genentech and the world's biotechnology industry.

Over 700,000 Americans have Crohn's Disease. It generally strikes individuals between 15 and 35. Crohn's disease belongs to a group of conditions known as Inflammatory Bowel Diseases (IBD). Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract.
Crohn's most commonly affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the gastrointestinal (GI) tract, from the mouth to the anus.

There is no known cure.

Who is Glenn Diamond?
From Fortune Magazine:
"Perhaps the most remarkable member of the damn-the-torpedoes set is Glenn "Buddy" Diamond, an entrepreneur who set out six years ago to mitigate his son's Down syndrome. That congenital disorder causes not only retardation but also progressive brain damage much like that of Alzheimer's. Starting with zero funding and no drug industry experience, Diamond managed to light a fire under the development of both the Russian and the Novartis drugs, enlist some of biotech's leading lights to back his cause, and inspire the formation of David Pharmaceuticals--the startup is named after his 9-year-old son.

Known to associates as a brilliant, uncompromising polymath, Diamond was a Minneapolis consultant on business turnarounds when David was born. He soon became a self-taught expert on Down syndrome."  See rest of the story here. (Glenn's story starts on the 22nd paragraph.)

Monday, May 27, 2013

NevBio Commercialization Briefing -New Opportunities for Southern Nevada - February 22, 2013

Join us and take part as we reshape Southern Nevada with new opportunities.

Friday, February 22nd
McCormick & Schmicks
11:30 am reg, 12 pm lunch & briefs
RSVP Free here ($30 normal charge)

Marty Schiller, PhD, UNLV; Treating HIV/Aids and other diseases with Genomic Surgery (New base of biotechnology, hundreds of job, $ billion market). SciReader - an app that can be used by every STEM student in the world. Huge potential.

Francis Tsang, PhD, National Labs, Medical Isotopes (The US imports all of its medical isotopes. $1 billion industry in the US, thousands of job in Nevada.) E-beam for cancer tumors can be used in every cancer center in the world.

Ernest Abel-Santos, PhD, UNLV; Treatment to prevent for C-Diff infections. Needed in every hospital, clinic and nursing home - $ billion market.

Opportunities like this, raise all of the boats. This is an important step toward new, home-grown industry in Southern Nevada.

Tech Transfer in the University System - Rich Helfrich, December 11, 2012

Rich Helfrich
Richard Helfrich, CEO of Alameda Advisors "Converting Innovations to Sustainable Businesses"
*Tuesday, December 11th
*11:30 check-in,12 pm lunch/talk *MCormick & Schmicks
*$30 RSVP here. UNLV Researchers & students - no cost.

Richard W. Helfrich is the President of Alameda Advisors. His team has helped commercialize innovations from universities, government labs and corporations, converting complex technology and life science ideas into businesses.
 Richard is an entrepreneur. He has started a number of companies. One of his startups is on NASDAQ.  He sits on a number of boards in advanced materials, alternative energy, semiconductors, medical, and communications hardware.
He has an AB degree in Physics, an MS in Electrical Engineering and a premed education covering chemistry & biochemistry.
Richard Helfrich supports improving economic growth and the quality of life through technology and a technology- savvy workforce. Richard supports programs for expanded K-12 science education, reduced regulatory and governance burdens for small business, and programs to encourage more spinouts/startups from federally funded and corporate research.

Alameda Advisors Inc. converts innovations to sustainable businesses:
* Maximizing results from intellectual property
* Converting innovations to companies via spinouts
 * Providing Silicon Valley connections
* Arranging efficient and effective Cleantech Solutions

The company "Converts innovations to Profits".

Attend University of Nevada School of Medicine, Dean Thomas Schwenk - February 13, 2013

Nevada Biotechnology & Health Science Consortium and Southern Nevada Medical Industry Coalition present
Dr. Thomas Schwenk, Dean of the University of Nevada School of Medicine
Date: Wednesday, February 13th
Time: 11:30 reg, 12 pm lunch
Cost: $30
Location: Fogo de Chao (new location)

Thomas L. Schwenk, M.D., is dean of the University of Nevada School of Medicine.
Schwenk earned his M.D. degree in 1975 from the University of Michigan Medical School. In 2002 he was elected to the Institute of Medicine of the United States National Academy of Sciences. 
His research focuses on the diagnosis and treatment of depression in primary care.
Schwenk spent much of his career at the University of Michigan. He joined the faculty of the Department of Family Medicine in 1984, was appointed interim chair of the department in 1986, and was named permanent chair in 1988. He also served as a professor in the Department of Medical Education and as associate director of the University of Michigan Depression Center. In June 2007 he was installed as the Chair of Family Medicine. In July 2011 Schwenk left Michigan to become dean of the University of Nevada School of Medicine.
The luncheon will be at a new location!
Fogo de Chao 360 E. Flamingo (Right next to McCormick & Schmicks). We have over 90 attending this joint meeting. Please get there early.

Southern Nevada Medical Industry Coalition is co-hosting. It is a non-profit 600-plus volunteer organization of healthcare professionals committed to improving access and delivery of medical care in Southern Nevada. 

Chancellor Dan Klaich & Former Jim Rogers - January 22, 2013

Please join us for Dan Klaich, Chancellor of the Nevada System of Higher Education (NSHE) & Jim Rogers, former Chancellor of NSHE
DATE: Tuesday, January 22nd
LOCATION: McCormick & Schmicks
CHECK-IN: 11:30 am, Lunch 12 noon
RSVP: Here. $30 (UNLV Researchers & Students no charge)

Chancellor Klaich will talk about a number of issues:
* Fair funding of higher education in Southern & Northern Nevada
* Vision for Higher Education in Nevada.
* The UNLV Events Center.
* Greater presence of School of Medicine in Southern Nevada.

Jim Rogers will talk about:
* Need for research
* Serving a diverse student population

In May 2004, Jim Rogers was appointed to serve as the Chancellor of the Nevada System of Higher Education. Jim served as the Chancellor through June 2009.
In 1999 Jim was listed as one of the "top 11 philanthropists in the nation" by Time magazine having given or pledged more than $275 million to various colleges and universities.
Jim earned a B.S. in accounting and an LL.B. from the University of Arizona and an LL.M. from the University of Southern California. Jim is the founder and owner of Intermountain West Communications which owns and operates 11 NBC and FOX affiliate TV stations in five Western states.

Dan Klaich has been the Chancellor since June 18, 2009. Previously he was vice chancellor. Dan is an attorney. He is a 1972 graduate of the University of Nevada, Reno with a Bachelor of Science in Accounting. He received his JD from the University of Washington School of Law.  Dan served on the Board of Regents of the NSHE from 1983 to 1997, including two terms as Chairman of the Board.